Zacks Investment Research downgraded shares of Avinger (NASDAQ:AVGR) from a buy rating to a hold rating in a research report sent to investors on Wednesday, Zacks.com reports.
According to Zacks, “Avinger, Inc. is engaged in designing, manufacturing and selling image-guided, catheter-based systems to treat peripheral arterial disease. The company’s product consists of Lightbox imaging console, Wildcat, Kittycat, Ocelot, Ocelot PIXL, Ocelot MVRX and Juicebox. Avinger, Inc. is based in Redwood City, California. “
Other analysts also recently issued research reports about the stock. Aegis began coverage on shares of Avinger in a report on Thursday, September 12th. They set a buy rating for the company. ValuEngine raised shares of Avinger from a hold rating to a buy rating in a report on Wednesday, September 25th.
Shares of AVGR stock traded up $0.08 during midday trading on Wednesday, hitting $1.45. 1,005,874 shares of the company were exchanged, compared to its average volume of 432,986. The firm has a market capitalization of $9.68 million, a P/E ratio of -0.04 and a beta of 1.66. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.09 and a current ratio of 1.37. The firm’s 50 day moving average price is $1.02 and its two-hundred day moving average price is $1.29. Avinger has a 52 week low of $0.77 and a 52 week high of $12.60.
Avinger (NASDAQ:AVGR) last announced its earnings results on Tuesday, November 5th. The medical device company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.10). The company had revenue of $2.41 million for the quarter. Avinger had a negative return on equity of 197.22% and a negative net margin of 237.51%. Analysts expect that Avinger will post -2.14 EPS for the current year.
An institutional investor recently bought a new position in Avinger stock. Wedbush Securities Inc. bought a new position in shares of Avinger Inc (NASDAQ:AVGR) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 76,056 shares of the medical device company’s stock, valued at approximately $63,000. Wedbush Securities Inc. owned 1.18% of Avinger as of its most recent filing with the SEC. Institutional investors own 18.42% of the company’s stock.
Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.
Read More: G-20
Get a free copy of the Zacks research report on Avinger (AVGR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Avinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avinger and related companies with MarketBeat.com's FREE daily email newsletter.